Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maja Reimann

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Frontiers in Microbiology|October 19, 2018
Evaluation of Galactomannan Testing, the <i>Aspergillus</i>-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary AspergillosisHelmut J F Salzer, Juergen Prattes, Holger Flick, et al.
The Journal of Infection|November 20, 2025
Lipoarabinomannan (LAM) for the diagnosis of tuberculosis from sputumSteffen Pichlo, Patricia Sanchez Carballo, Maja Reimann, et al.
Frontiers in Immunology|June 29, 2026
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapyJohanna Eggeling, Martina Sester, Christoph Lange, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 25, 2023
Update on the diagnosis of tuberculosisIrina Kontsevaya, Andrea Maurizio Cabibbe, Daniela Maria Cirillo, et al.
Pathogens & Immunity|June 28, 2024
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant TuberculosisNika Zielinski, Dragos Baiceanu, Antonela Dragomir, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2021
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA SequencingHans-Peter Grobbel, Matthias Merker, Niklas Köhler, et al.
Tuberculosis (Edinburgh, Scotland)|February 13, 2026
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation studyEmily Behrens, Niklas Köhler, Max Münchow, et al.
ACS Infectious Diseases|June 28, 2022
Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in TuberculosisJulius Brandenburg, Jan Heyckendorf, Franziska Marwitz, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 27, 2021
Perspectives for systems biology in the management of tuberculosisIrina Kontsevaya, Christoph Lange, Patricia Comella-Del-Barrio, et al.
Nature Medicine|February 16, 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trialAndreas H Diacon, Clifton E Barry, Alex Carlton, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Frontiers in Microbiology|October 19, 2018
Evaluation of Galactomannan Testing, the <i>Aspergillus</i>-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary AspergillosisHelmut J F Salzer, Juergen Prattes, Holger Flick, et al.
The Journal of Infection|November 20, 2025
Lipoarabinomannan (LAM) for the diagnosis of tuberculosis from sputumSteffen Pichlo, Patricia Sanchez Carballo, Maja Reimann, et al.
Frontiers in Immunology|June 29, 2026
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapyJohanna Eggeling, Martina Sester, Christoph Lange, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|July 25, 2023
Update on the diagnosis of tuberculosisIrina Kontsevaya, Andrea Maurizio Cabibbe, Daniela Maria Cirillo, et al.
Pathogens & Immunity|June 28, 2024
A Transcriptomic Biomarker Predicting Linezolid-Associated Neuropathy During Treatment of Drug-Resistant TuberculosisNika Zielinski, Dragos Baiceanu, Antonela Dragomir, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2021
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA SequencingHans-Peter Grobbel, Matthias Merker, Niklas Köhler, et al.
Tuberculosis (Edinburgh, Scotland)|February 13, 2026
Towards model-informed precision dosing of clofazimine, moxifloxacin, and terizidone/cycloserine in the treatment of drug-resistant tuberculosis: An external model evaluation studyEmily Behrens, Niklas Köhler, Max Münchow, et al.
ACS Infectious Diseases|June 28, 2022
Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in TuberculosisJulius Brandenburg, Jan Heyckendorf, Franziska Marwitz, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|May 27, 2021
Perspectives for systems biology in the management of tuberculosisIrina Kontsevaya, Christoph Lange, Patricia Comella-Del-Barrio, et al.
Nature Medicine|February 16, 2024
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trialAndreas H Diacon, Clifton E Barry, Alex Carlton, et al.
Pageof 4